AstraZeneca: Lynparza approved for prostate cancer
(CercleFinance.com) - AstraZeneca announces that the Lynparza (olaparib) + abiraterone and prednisone or Lynparza + prednisolone regimens have been approved in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutation (BRCAm).
This approval is based on a phase III trial that showed Lynparza + abiraterone resulted in very clinically meaningful improvements in both radiographic progression-free survival (rPFS) and overall survival compared to abiraterone alone.
The results of this trial showed that the Lynparza combination demonstrated a remarkable clinically significant benefit that should rapidly be considered the gold standard treatment for patients with metastatic castration-resistant BRCA-mutated prostate cancer, the Duke Cancer Institute, Durham, North Carolina noted.
Prostate cancer is the second most common cancer in men, and despite an increase in the number of treatments available for patients with mCRPC, five-year survival rates remain low.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This approval is based on a phase III trial that showed Lynparza + abiraterone resulted in very clinically meaningful improvements in both radiographic progression-free survival (rPFS) and overall survival compared to abiraterone alone.
The results of this trial showed that the Lynparza combination demonstrated a remarkable clinically significant benefit that should rapidly be considered the gold standard treatment for patients with metastatic castration-resistant BRCA-mutated prostate cancer, the Duke Cancer Institute, Durham, North Carolina noted.
Prostate cancer is the second most common cancer in men, and despite an increase in the number of treatments available for patients with mCRPC, five-year survival rates remain low.
Copyright (c) 2023 CercleFinance.com. All rights reserved.